fulvestrant
SpainDrugs containing this active substance
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is locally advanced or metastatic. It is also used in combination with palbociclib for women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or metastatic.
Form: solution for injection
Active substance Dosage fulvestrant 250 mg Manufacturer: Bexal Farmaceutica S.A.
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is locally advanced or metastatic. It is also used in combination with palbociclib to treat women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or metastatic.
Form: solution for injection in a pre-filled syringe
Active substance Dosage fulvestrant 50.0 mg Manufacturer: Ever Valinject Gmbh
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is locally advanced or metastatic. It can also be used in combination with palbociclib to treat women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer, whether in a postmenopausal or premenopausal state (in the latter case, together with another medication called a luteinizing hormone-releasing hormone agonist).
Form: solution for injection in a pre-filled syringe
Active substance Dosage fulvestrant 250 mg Manufacturer: Astrazeneca Ab
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is locally advanced or metastatic. It is also used in combination with palbociclib to treat women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or metastatic.
Form: solution for injection in a pre-filled syringe
Active substance Dosage fulvestrant 250 mg Manufacturer: Reddy Pharma Iberia S.A.
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is locally advanced or metastatic. It is also used in combination with palbociclib to treat women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or metastatic.
Form: solution for injection
Active substance Dosage fulvestrant 50 mg/ml Manufacturer: Eugia Pharma (Malta) Limited
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is localized or has spread to other parts of the body. It can also be used in combination with palbociclib to treat women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer.
Form: solution for injection
Active substance Dosage fulvestrant 250 mg Manufacturer: Laboratorio Stada S.L.
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is localized or has spread to other parts of the body. It can also be used in combination with palbociclib to treat hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer.
Form: solution for injection in a pre-filled syringe
Active substance Dosage fulvestrant 250 mg Manufacturer: Laboratorio Stada S.L.
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is locally advanced or metastatic. It can also be used in combination with palbociclib to treat women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer, whether locally advanced or metastatic.
Form: solution for injection in a pre-filled syringe
Active substance Dosage fulvestrant 250 mg Manufacturer: Teva Pharma S.L.U.
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is locally advanced or metastatic. It is also used in combination with palbociclib to treat women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer (that is locally advanced or metastatic).
Form: solution for injection
Active substance Dosage fulvestrant 50 mg/ml Manufacturer: Glenmark Arzneimittel Gmbh
-
It is used to treat postmenopausal women with estrogen receptor-positive breast cancer that is locally advanced or metastatic. It is also used in combination with palbociclib to treat women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or metastatic.
Form: solution for injection in a pre-filled syringe
Active substance Dosage fulvestrant 50 mg Manufacturer: Adamed Laboratorios S.L.U.
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is locally advanced or metastatic. It can also be used in combination with palbociclib to treat women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer (that is locally advanced or metastatic).
Form: solution for injection in a pre-filled syringe
Active substance Dosage fulvestrant 250 mg Manufacturer: Teva Pharma S.L.U.
-
It is used to treat postmenopausal women with a type of estrogen receptor-positive breast cancer that is locally advanced or metastatic. It can also be used in combination with palbociclib to treat women with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or metastatic.
Form: solution for injection
Active substance Dosage fulvestrant 250 mg Manufacturer: Accord Healthcare S.L.U.